Randomized, double-blind, placebo-controlled study of safety and efficacy of miltefosine in antihistamine-resistant chronic spontaneous urticaria

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 3, 2013, Pages

  Magerl, M ^a   Rother, M ^b   Bieber, T ^c   Biedermann, T ^d   Brasch, J ^e   Dominicus, R ^f   Hunzelmann, N ^g   Jakob, T ^h   Mahler, V ⁱ   Popp, G ^j   Schakel K ^k   Schlingensiepen, R ^l   Schmitt, J ^k,m   Siebenhaar, F ^a   Simon, J C ⁿ   Staubach, P ^o   Wedi, B ^p   Weidner, C ^q   Maurer, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b X pert Med GmbH   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Praxisklinik und Gemeinschaftspraxis   (Germany)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^j Licca Clinical Research Institute   (Germany)

^k UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^l JADO Technologies GmbH   (Germany)

^m DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁿ Universitätklinikum Leipzig ^*  (Germany)

^o UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^p HANNOVER MEDICAL SCHOOL   (Germany)

^q X pert Med GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; LEVOCETIRIZINE; LORATADINE; MILTEFOSINE; MIZOLASTINE; PLACEBO;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CHRONIC SPONTANEOUS URTICARIA; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; URTICARIA; URTICARIA ACTIVITY SCORE; VOMITING;

CHRONIC DISEASE; DOUBLE-BLIND METHOD; HISTAMINE ANTAGONISTS; HUMANS; PHOSPHORYLCHOLINE; PLACEBOS; URTICARIA;

EID: 84874113715     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04689.x     Document Type: Article

References (22)

1. Zuberbier T,. Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses. J Eur Acad Dermatol Venereol 2012; 26: 9-18.
2. Gelfand EW,. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004; 114: S135-138.
3. Maurer M, Metz M, Magerl M, Siebenhaar F, Staubach P,. Autoreactive urticaria and autoimmune urticaria. Hautarzt 2004; 55: 350-356.
4. Hakim-Rad K, Metz M, Maurer M,. Mast cells: makers and breakers of allergic inflammation. Curr Opin Allergy Clin Immunol 2009; 9: 427-430.
5. Zuberbier T, Maurer M,. Antihistamines in the treatment of urticaria. Adv Exp Med Biol 2010; 709: 67-72.
6. Zuberbier T, Maurer M,. Antihistamines in the treatment of urticaria. Adv Exp Med Biol 2011; 709: 67-72.
7. Monroe E,. Review of H1 antihistamines in the treatment of chronic idiopathic urticaria. Cutis 2005; 76: 118-126.
8. Hore I, Georgalas C, Scadding G,. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis - a systematic review of randomized controlled trials. Clin Exp Allergy 2005; 35: 207-212.
9. Barratt G, Saint-Pierre-Chazalet M, Loiseau PM,. Cellular transport and lipid interactions of miltefosine. Curr Drug Metab 2009; 10: 247-255.
10. Silveira ESAM, Mazucato VM, Jamur MC, Oliver C,. Lipid rafts in mast cell biology. J Lipids 2011; 2011: 752906.
11. Leonard R, Hardy J, Van Tienhoven G, et al. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 2001; 19: 4150-4159.
12. Rahman M, Ahmed BN, Faiz MA, et al. Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in Bangladesh. Am J Trop Med Hyg 2011; 85: 66-69.
13. Hartmann K, Siebenhaar F, Belloni B, et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2010; 162: 185-190.
14. Weller K, Artuc M, Jennings G, et al. Miltefosine inhibits human mast cell activation and mediator release both in vitro and in vivo. J Invest Dermatol 2009; 129: 496-498.
15. Menez C, Buyse M, Farinotti R, Barratt G,. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids 2007; 42: 229-240.
16. Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010; 65: 516-528.
17. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010; 125: 676-682.
18. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M,. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777-780.
19. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
20. Mlynek A, Magerl M, Hanna M, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy 2009; 64: 927-936.
21. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy 2005; 60: 1073-1078.
22. Colditz GA, Miller JN, Mosteller F,. Measuring gain in the evaluation of medical technology The probability of a better outcome. Int J Technol Assess Health Care 1988; 4: 637-642.